CC-3

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameCC-3
Drug Alias NameCC-3
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionCD276 antigen inhibitors
TargetsT cell surface glycoprotein CD3CD276 antigen
Therapy Area/IndicationsPenile NeoplasmsColorectal NeoplasmsGastrointestinal Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesEberhard Karls University Of Tubingen, Germany
China Registration ClassN/A

Develop Information

Active CompaniesEberhard Karls University Of Tubingen, GermanyGerman Cancer Research Center (Dkfz)
Inactive CompaniesN/A
Active IndicationsPenile NeoplasmsColorectal NeoplasmsGastrointestinal Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A